Oxford Genetics Overview
- Founded
- 2011
- Status
- Private
- Employees
- 71
- Latest Deal Type
- Later Stage VC
- Latest Deal Amount
- $3.73M
- Investors
- 5
Oxford Genetics General Information
Description
Developer biology-based technologies designed to aid in the discovery and development of biologics, cell, and gene therapies. The company's technologies specialize in DNA design, protein expression optimization, and cell line development technologies along with cloning platform and access to a library of matched plasmid inserts, enabling the bio-therapeutic industry to improve the overall efficiency through the application of synthetic biology.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
- Medawar Centre
- Robert Robinson Avenue
- Oxford OX4 4GA
- England, United Kingdom
+44 01865 000000
Oxford Genetics Timeline
Oxford Genetics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Later Stage VC | 06-May-2020 | $3.73M | 000.00 | Completed | Generating Revenue | |
| 11. Later Stage VC | 28-Mar-2019 | 00.000 | 000.00 | 000.00 | Completed | Generating Revenue |
| 10. Later Stage VC | 21-Aug-2017 | 000.00 | 000.00 | 000.00 | Completed | Generating Revenue |
| 9. Grant | 14-Feb-2017 | 00.000 | 00.000 | Completed | Generating Revenue | |
| 8. Early Stage VC | 27-Oct-2016 | 00.000 | 00.000 | 00.000 | Completed | Generating Revenue |
| 7. Early Stage VC | 17-Mar-2016 | 00.000 | 00.000 | 00.000 | Completed | Generating Revenue |
| 6. Early Stage VC | 01-Dec-2015 | 00000 | 00.000 | 00.000 | Completed | Startup |
| 5. Early Stage VC | 09-Jun-2015 | 00000 | 00000 | 00.000 | Completed | Startup |
| 4. Early Stage VC | 24-Dec-2014 | $313K | $733K | 00.000 | Completed | Startup |
| 3. Early Stage VC | 30-Jul-2014 | $137K | $420K | 00.000 | Completed | Startup |
Oxford Genetics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| C Ordinary | 00,000 | 00.000000 | 0000.0 | 0000.0 | 00 | 0000.0 | 00.000 | |
| C Ordinary | 0,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | |
| C Ordinary | 00,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 00.000 | |
| B Ordinary | 0,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | |
| B Ordinary | 0,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | |
| A Ordinary | 0,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.00 | |
| A Ordinary | 0,000 | 00.000000 | 000.0 | 000.0 | 00 | 000.0 | 0.000 | |
| A Ordinary | 0,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | |
| A Ordinary | 1,813 | $0.013184 | $58.17 | $58.17 | 1x | $58.17 | 1.9% | |
| A Ordinary | 3,400 | $0.013184 | $58.17 | $58.17 | 1x | $58.17 | 3.57% |
Oxford Genetics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer biology-based technologies designed to aid in the discovery and development of biologics, cell, and gene thera
Biotechnology
Oxford, United Kingdom
71
As of 2019
000.00
0000000000 0
000.00
0000000
amco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volu
0000000000000
London, United Kingdom
00
As of 0000
000
0000-00-00
000000&0
000000
aboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate
0000000000000
Cambridge, United Kingdom
000
As of 0000
0000
0000000 0000
0000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialOxford Genetics Competitors (20)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bioline Reagents | Formerly Accelerator/Incubator backed | London, United Kingdom | 00 | 000000&0 | ||
| 000000 | Private Equity-Backed | Cambridge, United Kingdom | 000 | 0000 | 0000000 0000 | 0000 |
| 00000000 | Corporation | Alameda, CA | 00 | 000000000 - | ||
| 0000000 000000000 | Formerly VC-backed | Tianjin, China | 000 | 00000 | 00000000 | 00000 |
| 0000 000000000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 00000000 | 00000 |
Oxford Genetics Executive Team (7)
Oxford Genetics Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Barry Hames Ph.D | Self | Non-Executive Chairman | 000 0000 |
| Leonard Seymour | Oxford Genetics | Co-Founder, Chief Scientist & Board Member | 000 0000 |
| Mark Payton Ph.D | Mercia Asset Management | Board Member & Advisor | 000 0000 |
| Martin Hall | Oxford Genetics | Chief Financial Officer & Board Member | 000 0000 |
| Matthew Baker Ph.D | Self | Board Member | 000 0000 |
Oxford Genetics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialOxford Genetics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Canaccord Genuity | Investment Bank | Minority | 000 0000 | 000000 0 | |
| Invesco | Asset Manager | Minority | 000 0000 | 000000 0 | |
| Innovate UK | Government | 000 0000 | 000000 0 | ||
| Invesco Perpetual | Asset Manager | Minority | 000 0000 | 000000 0 | |
| Mercia Asset Management | Venture Capital | Minority | 000 0000 | 000000 0 |